Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2455-2463

  Zhang, Tong ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CD3 ANTIGEN; CD3DELTA ANTIGEN; CHIMERIC NATURAL KILLER CELL RECEPTOR NKG2D; CHIMERIC PROTEIN; GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKG2D LIGAND RAE1; PERFORIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CAPILLARY TUBE; CARCINOGENESIS; CELL CONTACT; CONTROLLED STUDY; DNA MODIFICATION; DRUG TARGETING; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; ANTIGENS, CD3; BIOLOGICAL ASSAY; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MUTANT CHIMERIC PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; NUCLEAR MATRIX-ASSOCIATED PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PORE FORMING CYTOTOXIC PROTEINS; PRIMARY CELL CULTURE; RETROVIRIDAE; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84874285199     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201314     Document Type: Article

References (55)

1. Chouaib, S., C. Kieda, H. Benlalam, M. Z. Noman, F. Mami-Chouaib, and C. Rüegg. 2010. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit. Rev. Immunol. 30: 529-545.
2. Kerbel, R. S. 2008. Tumor angiogenesis. N. Engl. J. Med. 358: 2039-2049.
3. Rakhra, K., P. Bachireddy, T. Zabuawala, R. Zeiser, L. Xu, A. Kopelman, A. C. Fan, Q. Yang, L. Braunstein, E. Crosby, et al. 2010. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18: 485-498.
4. Schoenfeld, J., M. Jinushi, Y. Nakazaki, D. Wiener, J. Park, R. Soiffer, D. Neuberg, M. Mihm, F. S. Hodi, and G. Dranoff. 2010. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 70: 10150-10160.
5. Los, M., J. M. Roodhart, and E. E. Voest. 2007. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450.
6. Chinnasamy, D., Z. Yu, M. R. Theoret, Y. Zhao, R. K. Shrimali, R. A. Morgan, S. A. Feldman, N. P. Restifo, and S. A. Rosenberg. 2010. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120: 3953-3968.
7. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
8. Nausch, N., I. E. Galani, E. Schlecker, and A. Cerwenka. 2008. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 112: 4080-4089.
9. Zhang, T., and C. L. Sentman. 2011. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 71: 2066-2076.
10. Barber, A., A. Rynda, and C. L. Sentman. 2009. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J. Immunol. 183: 6939-6947.
11. Stern-Ginossar, N., N. Elefant, A. Zimmermann, D. G. Wolf, N. Saleh, M. Biton, E. Horwitz, Z. Prokocimer, M. Prichard, G. Hahn, et al. 2007. Host immune system gene targeting by a viral miRNA. Science 317: 376-381.
12. Arnaud, L., J. Haroche, A. Mathian, G. Gorochov, and Z. Amoura. 2011. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev. 11: 61-67.
13. Zhang, T., A. Barber, and C. L. Sentman. 2006. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66: 5927-5933.
14. Zhang, T., B. A. Lemoi, and C. L. Sentman. 2005. Chimeric NK-receptorbearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551.
15. Eriksson, M., S. K. Meadows, S. Basu, T. F. Mselle, C. R. Wira, and C. L. Sentman. 2006. TLRs mediate IFN-gamma production by human uterine NK cells in endometrium. J. Immunol. 176: 6219-6224.
16. Zhang, T., A. Barber, and C. L. Sentman. 2007. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67: 11029-11036.
17. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190.
18. Hammond, E. M., N. C. Denko, M. J. Dorie, R. T. Abraham, and A. J. Giaccia. 2002. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22: 1834-1843.
19. Hammond, E. M., M. J. Dorie, and A. J. Giaccia. 2003. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278: 12207-12213.
20. Hammond, E. M., M. J. Dorie, and A. J. Giaccia. 2004. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res. 64: 6556-6562.
21. Garlanda, C., C. Parravicini, M. Sironi, M. De Rossi, R.Wainstok de Calmanovici, F. Carozzi, F. Bussolino, F. Colotta, A. Mantovani, and A. Vecchi. 1994. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc. Natl. Acad. Sci. USA 91: 7291-7295.
22. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163-189.
23. Belperio, J. A., M. P. Keane, D. A. Arenberg, C. L. Addison, J. E. Ehlert, M. D. Burdick, and R. M. Strieter. 2000. CXC chemokines in angiogenesis. J. Leukoc. Biol. 68: 1-8.
24. Ferrara, N., and R. S. Kerbel. 2005. Angiogenesis as a therapeutic target. Nature 438: 967-974.
25. Rossig, C., and M. K. Brenner. 2004. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol. Ther. 10: 5-18.
26. Ho, W. Y., J. N. Blattman, M. L. Dossett, C. Yee, and P. D. Greenberg. 2003. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3: 431-437.
27. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hämmerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62: 1462-1470.
28. Gajewski, T. F., Y. Meng, C. Blank, I. Brown, A. Kacha, J. Kline, and H. Harlin. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213: 131-145.
29. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
30. Quezada, S. A., K. S. Peggs, T. R. Simpson, Y. Shen, D. R. Littman, and J. P. Allison. 2008. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205: 2125-2138.
31. Ohm, J. E., D. I. Gabrilovich, G. D. Sempowski, E. Kisseleva, K. S. Parman, S. Nadaf, and D. P. Carbone. 2003. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101: 4878-4886.
32. Mulligan, J. K., S. A. Rosenzweig, and M. R. Young. 2010. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J. Immunother. 33: 126-135.
33. Motz, G. T., and G. Coukos. 2011. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11: 702-711.
34. Shrimali, R. K., Z. Yu, M. R. Theoret, D. Chinnasamy, N. P. Restifo, and S. A. Rosenberg. 2010. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70: 6171-6180.
35. Li, Y., M. N. Wang, H. Li, K. D. King, R. Bassi, H. Sun, A. Santiago, A. T. Hooper, P. Bohlen, and D. J. Hicklin. 2002. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195: 1575-1584.
36. Roy, S., P. F. Barnes, A. Garg, S. Wu, D. Cosman, and R. Vankayalapati. 2008. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 180: 1729-1736.
37. Murdoch, C., M. Muthana, S. B. Coffelt, and C. E. Lewis. 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8: 618-631.
38. Facciabene, A., X. Peng, I. S. Hagemann, K. Balint, A. Barchetti, L. P. Wang, P. A. Gimotty, C. B. Gilks, P. Lal, L. Zhang, and G. Coukos. 2011. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475: 226-230.
39. Hammond, E. M., and A. J. Giaccia. 2002. Antiangiogenic therapy and p53. Science 297: 471.
40. Hamerman, J. A., K. Ogasawara, and L. L. Lanier. 2004. Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J. Immunol. 172: 2001-2005.
41. Hagemann, T., T. Lawrence, I. McNeish, K. A. Charles, H. Kulbe, R. G. Thompson, S. C. Robinson, and F. R. Balkwill. 2008. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205: 1261-1268.
42. Whiteside, T. L. 2008. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912.
43. Yao, L., C. Sgadari, K. Furuke, E. T. Bloom, J. Teruya-Feldstein, and G. Tosato. 1999. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93: 1612-1621.
44. Strasly, M., F. Cavallo, M. Geuna, S. Mitola, M. P. Colombo, G. Forni, and F. Bussolino. 2001. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166: 3890-3899.
45. Barber, A., T. Zhang, and C. L. Sentman. 2008. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J. Immunol. 180: 72-78.
46. Rüegg, C., A. Yilmaz, G. Bieler, J. Bamat, P. Chaubert, and F. J. Lejeune. 1998. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 4: 408-414.
47. Ray, P. S., and P. L. Fox. 2007. A post-transcriptional pathway represses monocyte VEGF-A expression and angiogenic activity. EMBO J. 26: 3360-3372.
48. Kanegane, C., C. Sgadari, H. Kanegane, J. Teruya-Feldstein, L. Yao, G. Gupta, J. M. Farber, F. Liao, L. Liu, and G. Tosato. 1998. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukoc. Biol. 64: 384-392.
49. Potter, S., T. Chan-Ling, H. J. Ball, H. Mansour, A. Mitchell, L. Maluish, and N. H. Hunt. 2006. Perforin mediated apoptosis of cerebral microvascular endothelial cells during experimental cerebral malaria. Int. J. Parasitol. 36: 485-496.
50. Nakajima, T., S. Schulte, K. J. Warrington, S. L. Kopecky, R. L. Frye, J. J. Goronzy, and C. M. Weyand. 2002. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105: 570-575.
51. Choy, J. C., A. Kerjner, B. W. Wong, B. M. McManus, and D. J. Granville. 2004. Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. Am. J. Pathol. 165: 127-133.
52. Seko, Y., S. Minota, A. Kawasaki, Y. Shinkai, K. Maeda, H. Yagita, K. Okumura, O. Sato, A. Takagi, Y. Tada, et al. 1994. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J. Clin. Invest. 93: 750-758.
53. Chen, Q., S. Tong, M. W. Dewhirst, and F. Yuan. 2004. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol. Cancer Ther. 3: 1311-1317.
54. Cuttica, M. J., T. Langenickel, A. Noguchi, R. F. Machado, M. T. Gladwin, and M. Boehm. 2011. Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage. Am. J. Respir. Cell Mol. Biol. 45: 62-71.
55. Strieter, R. M., J. A. Belperio, R. J. Phillips, and M. P. Keane. 2004. CXC chemokines in angiogenesis of cancer. Semin. Cancer Biol. 14: 195-200.